Author

Luisa Chocarro

Observed names: Chocarro de Erauso, Luisa, Chocarro, Luisa, L Chocarro, L. Chocarro, L.D.E. Chocarro, Luisa Chocarro De Erauso, Luisa Chocarro de Erauso

Institutions: Universidad Pública de Navarra (UPNA), Navarre Institute of Health Research, Navarrabiomed

Observed institutions: Universidad Pública de Navarra (UPNA), University of Oxford, Complejo Hospitalario de Navarra, Navarre Institute of Health Research, Navarrabiomed, Centro de Investigación Médica Aplicada, University of Pamplona, Universidad de Navarra

ORCID: 0000-0001-7384-9847

Observed ORCID: 0000-0001-7384-9847

OpenAlex ID: A5089397863

Understanding LAG-3 Signaling

2021 · Luisa Chocarro, Ester Blanco, et al. · International Journal of Molecular Sciences · 216

Clinical landscape of LAG-3-targeted therapy

2022 · L. Chocarro, E. Blanco, et al. · Immuno-Oncology Technology · 99

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy

2020 · Miren Zuazo, Hugo Arasanz, et al. · Frontiers in Immunology · 92

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?

2020 · Luisa Chocarro de Erauso, Miren Zuazo, et al. · Frontiers in Pharmacology · 91

Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics

2020 · Hugo Arasanz, Miren Zuazo, et al. · Cancers · 89

mRNA Vaccines against SARS-CoV-2: Advantages and Caveats

2023 · Miriam Echaide, Luisa Chocarro de Erauso, et al. · International Journal of Molecular Sciences · 76

Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor

2022 · Luisa Chocarro, Ana Bocanegra, et al. · Cells · 70

Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy

2023 · Marta Redondo-Muñoz, Francisco Javier Rodriguez-Baena, et al. · Nature Metabolism · 61

Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer

2022 · H Arasanz, A Bocanegra, et al. · Cancers · 43

Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies

2020 · Carlos Hernandez, Hugo Arasanz, et al. · International Journal of Molecular Sciences · 38

How Can We Improve Vaccination Response in Old People? Part I: Targeting Immunosenescence of Innate Immunity Cells

2022 · Anna Aiello, Mattia Emanuela Ligotti, et al. · International Journal of Molecular Sciences · 35

Hyperprogressive Disease: Main Features and Key Controversies

2021 · Hugo Arasanz, Miren Zuazo, et al. · International Journal of Molecular Sciences · 31

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy

2020 · Miren Zuazo, Hugo Arasanz, et al. · EMBO Molecular Medicine · 29

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy

2020 · Ana Bocanegra, Ester Blanco, et al. · International Journal of Molecular Sciences · 24

PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets

2024 · Luisa Chocarro, Ester Blanco, et al. · EMBO Molecular Medicine · 20

CAR-T Cells for the Treatment of Lung Cancer

2022 · Luisa Chocarro, Hugo Arasanz, et al. · Life · 19

Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors

2023 · Ester Blanco, Luisa Chocarro, et al. · International Journal of Molecular Sciences · 18

How Can We Improve the Vaccination Response in Older People? Part II: Targeting Immunosenescence of Adaptive Immunity Cells

2022 · Maider Garnica, Anna Aiello, et al. · International Journal of Molecular Sciences · 18

Plasma fractalkine contributes to systemic myeloid diversity and PD‐L1/PD‐1 blockade in lung cancer

2023 · Ana Bocanegra, Gonzalo Fernández‐Hinojal, et al. · EMBO Reports · 17

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy

2022 · David Escors, Ana Bocanegra, et al. · International Journal of Molecular Sciences · 17

Fractalkine in Health and Disease

2024 · Claudia Rodriguez, Luisa Chocarro, et al. · International Journal of Molecular Sciences · 16

The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity

2021 · Carolyn J. Edwards, Angelica Sette, et al. · British Journal of Cancer · 16

Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination

2022 · Miriam Echaide, Ibone Labiano, et al. · Cancers · 15

Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies

2024 · Ester Blanco, Noelia Silva-Pilipich, et al. · British Journal of Cancer · 14

Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT Inhibition

2020 · Hugo Arasanz, Carlos Hernández, et al. · Cancers · 14

Works count: 64

Citation count: 1,230

H-index: 18

I10-index: 26